See more : Andlauer Healthcare Group Inc. (ANDHF) Income Statement Analysis – Financial Results
Complete financial analysis of Fresenius SE & Co. KGaA (FSNUY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fresenius SE & Co. KGaA, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
- Shinwa Co., Ltd. (3447.T) Income Statement Analysis – Financial Results
- Dalmia Bharat Sugar and Industries Limited (DALMIASUG.NS) Income Statement Analysis – Financial Results
- Shenzhen Dawei Innovation Technology Co., Ltd. (002213.SZ) Income Statement Analysis – Financial Results
- Great Elm Capital Corp. (GECC) Income Statement Analysis – Financial Results
- Cox Energy América, S.A.B. de C.V. (COX.MC) Income Statement Analysis – Financial Results
Fresenius SE & Co. KGaA (FSNUY)
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.30B | 40.84B | 37.52B | 36.28B | 35.41B | 33.53B | 33.89B | 29.08B | 27.63B | 23.23B | 20.33B | 19.29B | 16.52B | 15.97B | 14.16B | 12.34B | 11.36B | 10.78B | 7.89B | 7.27B | 7.06B | 7.51B |
| Cost of Revenue | 17.24B | 30.12B | 27.21B | 25.96B | 25.06B | 23.70B | 23.41B | 19.96B | 19.09B | 16.39B | 13.95B | 13.00B | 10.88B | 10.65B | 9.53B | 8.41B | 7.68B | 7.35B | 5.30B | 4.90B | 4.79B | 5.07B |
| Gross Profit | 5.06B | 10.73B | 10.31B | 10.32B | 10.35B | 9.83B | 10.48B | 9.13B | 8.53B | 6.84B | 6.38B | 6.29B | 5.64B | 5.33B | 4.64B | 3.93B | 3.68B | 3.43B | 2.59B | 2.38B | 2.28B | 2.44B |
| Gross Profit Ratio | 22.68% | 26.26% | 27.48% | 28.44% | 29.22% | 29.33% | 30.92% | 31.39% | 30.89% | 29.45% | 31.40% | 32.60% | 34.13% | 33.35% | 32.74% | 31.84% | 32.38% | 31.79% | 32.82% | 32.68% | 32.22% | 32.45% |
| Research & Development | 661.00M | 867.00M | 805.00M | 751.00M | 645.00M | 673.00M | 558.00M | 500.00M | 464.00M | 369.00M | 348.00M | 305.00M | 267.00M | 244.00M | 240.00M | 479.00M | -184.00M | -167.00M | -149.00M | -133.00M | 121.00M | 138.00M |
| General & Administrative | 2.41B | 5.52B | 4.39B | 4.37B | 4.39B | 3.86B | 4.59B | 3.39B | 3.28B | 2.52B | 2.24B | 2.25B | 2.81B | 2.66B | 2.34B | 1.97B | 1.89B | 0.00 | 0.00 | 0.00 | 1.37B | 1.46B |
| Selling & Marketing | 750.00M | 1.22B | 1.06B | 1.06B | 1.02B | 1.02B | 948.00M | 916.00M | 471.00M | 435.00M | 414.00M | 380.00M | 341.00M | 0.00 | 0.00 | 0.00 | -467.00M | -433.00M | -402.00M | -220.00M | 0.00 | 0.00 |
| SG&A | 3.16B | 6.74B | 5.45B | 5.43B | 5.41B | 4.87B | 5.54B | 4.30B | 3.75B | 2.95B | 2.66B | 2.63B | 2.81B | 2.66B | 2.34B | 1.97B | -467.00M | -433.00M | -402.00M | -220.00M | 1.37B | 1.46B |
| Other Expenses | 99.00M | -207.00M | -105.00M | -219.00M | -305.00M | -154.00M | -210.00M | 0.00 | 444.00M | 406.00M | 387.00M | 366.00M | -100.00M | -66.00M | -31.00M | 68.00M | 0.00 | 0.00 | 0.00 | 0.00 | -522.00M | -609.00M |
| Operating Expenses | 3.92B | 7.40B | 6.15B | 5.96B | 5.75B | 5.39B | 5.89B | 4.80B | 4.66B | 3.73B | 3.39B | 3.31B | 3.08B | 2.91B | 2.58B | 2.45B | -651.00M | -600.00M | -551.00M | -353.00M | 1.52B | 1.63B |
| Cost & Expenses | 21.16B | 37.52B | 33.36B | 31.92B | 30.81B | 29.09B | 29.30B | 24.76B | 23.75B | 20.12B | 17.34B | 16.31B | 13.96B | 13.55B | 12.11B | 10.86B | 7.03B | 6.75B | 4.75B | 4.54B | 6.31B | 6.70B |
| Interest Income | 114.00M | 187.00M | 124.00M | 93.00M | 162.00M | 355.00M | 197.00M | 96.00M | 255.00M | 128.00M | 50.00M | 54.00M | 56.00M | 30.00M | 22.00M | 25.00M | 27.00M | 0.00 | 0.00 | 0.00 | 297.00M | 345.00M |
| Interest Expense | 530.00M | 694.00M | 630.00M | 752.00M | 881.00M | 942.00M | 848.00M | 678.00M | 868.00M | 730.00M | 634.00M | 720.00M | 587.00M | 596.00M | 602.00M | 456.00M | 395.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.48B | 1.16B | 2.65B | 2.71B | 2.41B | 1.50B | 1.44B | 1.22B | 1.12B | 937.00M | 843.00M | 776.00M | 674.00M | 639.00M | 562.00M | 783.00M | 421.00M | 399.00M | 320.00M | 315.00M | 325.00M | 341.00M |
| EBITDA | 2.73B | 3.10B | 6.95B | 7.19B | 7.25B | 6.23B | 6.23B | 5.61B | 5.25B | 4.18B | 3.83B | 3.89B | 3.19B | 3.02B | 2.61B | 2.35B | 2.06B | 4.43B | 3.46B | 3.04B | 1.08B | 1.15B |
| EBITDA Ratio | 12.23% | 15.87% | 18.52% | 19.74% | 20.38% | 18.57% | 18.36% | 19.24% | 18.99% | 17.99% | 19.10% | 20.15% | 19.33% | 18.91% | 18.41% | 19.07% | 41.82% | 41.06% | 43.86% | 41.86% | 15.32% | 15.33% |
| Operating Income | 1.14B | 3.51B | 4.16B | 4.39B | 4.63B | 5.25B | 4.59B | 4.33B | 3.88B | 3.11B | 2.99B | 2.98B | 2.56B | 2.42B | 2.05B | 1.48B | 1.61B | 1.44B | 969.00M | 845.00M | 781.00M | 837.00M |
| Operating Income Ratio | 5.13% | 8.59% | 11.08% | 12.09% | 13.08% | 15.66% | 13.54% | 14.88% | 14.03% | 13.40% | 14.71% | 15.46% | 15.51% | 15.14% | 14.50% | 11.97% | 14.17% | 13.40% | 12.28% | 11.62% | 11.06% | 11.15% |
| Total Other Income/Expenses | -428.00M | -215.00M | -506.00M | -659.00M | -719.00M | -587.00M | -667.00M | -582.00M | -613.00M | -602.00M | -584.00M | -592.00M | -631.00M | -632.00M | -611.00M | -363.00M | -368.00M | -1.44B | -969.00M | -845.00M | -249.00M | -291.00M |
| Income Before Tax | 715.00M | 2.81B | 3.65B | 3.73B | 3.91B | 4.66B | 3.94B | 3.75B | 3.26B | 2.51B | 2.41B | 2.39B | 1.93B | 1.79B | 1.44B | 1.11B | 1.24B | 0.00 | 0.00 | 0.00 | 532.00M | 546.00M |
| Income Before Tax Ratio | 3.21% | 6.89% | 9.73% | 10.27% | 11.05% | 13.91% | 11.62% | 12.88% | 11.81% | 10.81% | 11.84% | 12.40% | 11.69% | 11.18% | 10.19% | 9.03% | 10.93% | 0.00% | 0.00% | 0.00% | 7.53% | 7.27% |
| Income Tax Expense | 477.00M | 697.00M | 833.00M | 903.00M | 883.00M | 950.00M | 905.00M | 1.05B | 965.00M | 700.00M | 669.00M | 659.00M | 604.00M | 581.00M | 452.00M | 440.00M | 3.92B | 3.70B | 2.92B | 2.56B | 223.00M | 202.00M |
| Net Income | -594.00M | 2.12B | 2.82B | 2.82B | 3.03B | 2.03B | 1.81B | 1.56B | 1.36B | 1.07B | 1.01B | 926.00M | 1.33B | 1.21B | 991.00M | 270.00M | 409.00M | 329.00M | 221.00M | 167.00M | 115.00M | 134.00M |
| Net Income Ratio | -2.66% | 5.18% | 7.51% | 7.78% | 8.55% | 6.05% | 5.35% | 5.36% | 4.92% | 4.59% | 4.97% | 4.80% | 8.04% | 7.54% | 7.00% | 2.19% | 3.60% | 3.05% | 2.80% | 2.30% | 1.63% | 1.79% |
| EPS | 0.37 | 3.77 | 5.05 | 5.06 | 5.44 | 0.91 | 0.82 | 0.71 | 0.62 | 0.49 | 0.47 | 0.45 | 0.68 | 0.62 | 0.51 | 0.14 | 0.22 | 0.18 | 0.15 | 0.34 | 0.23 | 0.27 |
| EPS Diluted | 0.63 | 3.77 | 5.05 | 5.06 | 5.43 | 0.91 | 0.81 | 0.71 | 0.62 | 0.49 | 0.47 | 0.44 | 0.67 | 0.62 | 0.51 | 0.13 | 0.22 | 0.18 | 0.15 | 0.34 | 0.23 | 0.27 |
| Weighted Avg Shares Out | 947.77M | 561.26M | 558.06M | 557.45M | 556.82M | 2.23B | 2.22B | 2.19B | 2.18B | 2.17B | 2.15B | 2.08B | 1.96B | 1.94B | 1.94B | 1.90B | 1.86B | 1.84B | 503.49M | 492.54M | 492.54M | 492.54M |
| Weighted Avg Shares Out (Dil) | 563.24M | 561.26M | 558.16M | 557.74M | 557.42M | 2.23B | 2.23B | 2.20B | 2.20B | 2.18B | 2.16B | 2.10B | 1.98B | 1.96B | 1.94B | 1.91B | 1.88B | 1.86B | 507.40M | 494.03M | 493.32M | 492.54M |
Fresenius to assess whether state aid impacts bonus, dividend payouts
Is Fresenius SE & Co. (FSNUY) a Great Value Stock Right Now?
Fresenius SE Probably Found Its Bottom
Fresenius SE & Co. KGaA (FSNUF) Q2 2023 Earnings Call Transcript
Fresenius: 90%+ Upside At This Time
Fresenius launches biosimilar version of AbbVie's Humira at 5% discount
Fresenius: Still Struggling, Still Undervalued
My Dividend Stock Portfolio: New All-Time Dividend Record - 99 Holdings With 25 Buys
Fresenius SE & Co. KGaA (FSNUF) Q4 2022 Earnings Call Transcript
Fresenius: One-Off Special Situation Opportunity To Buy
Source: https://incomestatements.info
Category: Stock Reports